Neurosom(R) Sleep Therapy Announces Participation in the Q4 Virtual Investor Summit

Eugene, Oregon--(Newsfile Corp. - November 8, 2021) - Neurosom® Sleep Therapy today announced that Justin Nichols, Director of NA Sales will be attending the Q4 Virtual Investor Summit. Justin Nichols, PhD and Neurosom® Director of NA Sales, will highlight Neurosom®'s recent successful clinical trial of Neurosom® Sleep Therapy, and publication in Sleep Medicine, as well as the broader company vision going forward.

Event: Q4 Investor Summit
Date: November 16-17th, 2021
Presentation: November 16th at 4:50PM ET
Location: https://us06web.zoom.us/webinar/register/WN_e6AXkHo8RXiJzqh2mr1RhA 

• 1x1s will be available for qualified investors
• The conference is completely complimentary to qualified investors. Please register at Complimentary Investor Registration.

About Neurosom® Sleep Therapy

Neurosom® Sleep Therapy is a wearable headband that can both accurately track EEG sleep cycles and extend deep sleep. Deep sleep has many possible health benefits, including clearance of neurotoxins, see our parent company's recent press: https://www.geekwire.com/2021/neurosciences-startup-gets-defense-dept-funds-test-headband-improve-sleep-clean-brain/.

For further information:

Neurosom® Sleep Therapy
Corin Tucker
5415259799
corin.tucker@bel.company

About the Investor Summit

The Investor Summit (formerly MicroCap Conference) is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors. The Q4 Investor Summit will take place virtually, featuring 90+ companies and over 500 investors comprising of institutional investors, family offices, and high net worth investors. Sectors Participating: Biotech, Communication Services, Consumer, Energy, Energy/Tech, Financial, Healthcare, Industrials, Materials, Real Estate, Technology, and Tech/Crypt. Contact: info@investorsummitgroup.com